Brazil's AI MedTech Surprise: Decoding ANVISA's New Rules with Pure Global

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

Brazil's AI MedTech Surprise: Decoding ANVISA's New Rules with Pure Global

Ascolta gratuitamente

Vedi i dettagli del titolo

3 mesi a soli 0,99 €/mese

Dopo 3 mesi, 9,99 €/mese. Si applicano termini e condizioni.

A proposito di questo titolo

This week, we dissect the breaking news from Brazil's regulatory landscape. ANVISA has just rolled out RDC 884, a new resolution that specifically targets AI and machine learning-powered medical software. This move signals a profound shift, moving Brazil away from reliance on foreign approvals and establishing a new, sophisticated framework for digital health technology. In this episode, we explore the critical details of this new regulation. We break down the stricter classification system, the controversial new requirements for localized clinical data, and the tough cybersecurity standards now being enforced. Learn what this means for MedTech innovators and how it will redefine the pathway to one of Latin America's largest markets. **Case Study:** Imagine you're a successful SaMD scale-up with FDA clearance, eyeing expansion. Your entire Brazilian market entry plan, built on leveraging your existing approvals, was just upended by ANVISA's announcement last week. Are you now required to run a costly and time-consuming local clinical trial? How do you prove your algorithm works for Brazil's unique population demographics? **This episode will answer:** - What are the three biggest changes in ANVISA's new AI software regulation? - Why might your existing FDA or CE Mark documentation now be rejected in Brazil? - Is a local clinical investigation mandatory for all AI-driven medical devices? - How can the new cybersecurity rules impact your product's architecture? - What are the hidden costs associated with the new data validation requirements? - Does this resolution create a new competitive advantage for locally-developed AI? - How should this change your strategic approach to the entire LATAM region? Struggling to keep up with regulatory shifts in Latin America? Pure Global offers end-to-end solutions for MedTech and IVD companies, combining local expertise with advanced AI tools to streamline global market access. Whether it's market strategy, local representation, or technical dossier submission, we make global expansion clear and efficient. Contact us at info@pureglobal.com or visit https://pureglobal.com/ to learn more.

Ancora nessuna recensione